Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
However, he added that until further de-risking of the pharmas obesity portfoliothrough strong efficacy and clean safety data in larger studieshis firm will continue to adopt a more conservative revenue estimate of $865 million by 2032, a far cry from AstraZenecas $5 billion peak projection for its metabolic business
It is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor, which can synergistically regulate appetite, calorie intake, and metabolic function
However, Ozempic is represented to be one of the GLP-1 receptor agonist medicines that was primarily developed to treat type 2 diabetes but has been discussed lately as regards overweight reduction medicines
Patients must work with healthcare providers to monitor their blood glucose levels and assess how the medication affects their overall health
Regular monitoring is advisable, particularly for patients taking anticoagulants or those with kidney disease, thyroid disorders, or cardiovascular conditions
